1
|
Steagall PV, Monteiro BP, Marangoni S, Moussa M, Sautié M. Fully automated deep learning models with smartphone applicability for prediction of pain using the Feline Grimace Scale. Sci Rep 2023; 13:21584. [PMID: 38062194 PMCID: PMC10703818 DOI: 10.1038/s41598-023-49031-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2023] [Accepted: 12/03/2023] [Indexed: 12/18/2023] Open
Abstract
This study used deep neural networks and machine learning models to predict facial landmark positions and pain scores using the Feline Grimace Scale© (FGS). A total of 3447 face images of cats were annotated with 37 landmarks. Convolutional neural networks (CNN) were trained and selected according to size, prediction time, predictive performance (normalized root mean squared error, NRMSE) and suitability for smartphone technology. Geometric descriptors (n = 35) were computed. XGBoost models were trained and selected according to predictive performance (accuracy; mean square error, MSE). For prediction of facial landmarks, the best CNN model had NRMSE of 16.76% (ShuffleNetV2). For prediction of FGS scores, the best XGBoost model had accuracy of 95.5% and MSE of 0.0096. Models showed excellent predictive performance and accuracy to discriminate painful and non-painful cats. This technology can now be used for the development of an automated, smartphone application for acute pain assessment in cats.
Collapse
Affiliation(s)
- P V Steagall
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, QC, Canada.
- Department of Veterinary Clinical Sciences and Centre for Animal Health and Welfare, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China.
| | - B P Monteiro
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, QC, Canada
| | - S Marangoni
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, QC, Canada
| | - M Moussa
- Plateforme IA-Agrosanté, Université de Montréal, Saint-Hyacinthe, QC, Canada
| | - M Sautié
- Plateforme IA-Agrosanté, Université de Montréal, Saint-Hyacinthe, QC, Canada
| |
Collapse
|
5
|
Saenz M, Bloom-Saldana EA, Synold T, Ermel RW, Fueger PT, Finlay JB. Pharmacokinetics of Sustained-release and Extended-release Buprenorphine in Mice after Surgical Catheterization. JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE : JAALAS 2022; 61:468-474. [PMID: 36008090 PMCID: PMC9536818 DOI: 10.30802/aalas-jaalas-22-000025] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The Guide for the Care and Use of Laboratory Animals strongly encourages the use of pharmaceutical-grade chemicals and analgesics. Sustained-release buprenorphine (SRB) is administered extralabel to rodents to mitigate moderate to severe pain. An FDA-indexed buprenorphine formulation-extended-release buprenorphine (XRB)-has recently become available and is currently the only pharmaceutical-grade slow-release buprenorphine formulation approved for use in mice and rats. However, no studies have directly compared the pharmacokinetic parameters of SRB and XRB in surgically catheterized mice. To this end, we compared the plasma buprenorphine concentrations and pharmacokinetic parameters of SRB and XRB in mice after surgical catheterization. We hypothesized that mice treated before surgery with SRB or XRB would have circulating buprenorphine concentrations that exceeded the therapeutic threshold for as long as 72 h after surgery. Male and female C57Bl/6J mice were anesthetized, treated with a single dose of either SRB (1 mg/kg SC) or XRB (3.25 mg/kg SC), and underwent surgical catheterization. Arterial blood samples were collected at 6, 24, 48, and 72 h after administration. Weight loss after surgery (mean ± SEM) was similar between groups (SRB: males, 12% ± 2%; females, 8% ± 2%; XRB: males, 12% ± 1%; females, 8% ± 1%). Both SRB and XRB maintained circulating buprenorphine concentrations above the therapeutic level of 1.0 ng/mL for 72 h after administration. Plasma buprenorphine concentrations at 6, 24, and 48 h were significantly greater (3- to 4-fold) with XRB than SRB, commensurate with XRB's higher dose. These results support the use of either SRB or XRB for the alleviation of postoperative pain in mice. The availability of FDA-indexed XRB increases options for safe and effective pharmaceutical-grade analgesia in rodents.
Collapse
Affiliation(s)
- Marissa Saenz
- Center for Comparative Medicine,,Department of Molecular and Cellular Endocrinology,,Corresponding author.
| | | | - Tim Synold
- Analytical Pharmacology Core, Beckman Research Institute, City of Hope National Medical Center, Duarte, California
| | | | - Patrick T Fueger
- Department of Molecular and Cellular Endocrinology,,Comprehensive Metabolic Phenotyping Core, and
| | | |
Collapse
|
6
|
Ceger P, Garcia-Reyero Vinas N, Allen D, Arnold E, Bloom R, Brennan JC, Clarke C, Eisenreich K, Fay K, Hamm J, Henry PFP, Horak K, Hunter W, Judkins D, Klein P, Kleinstreuer N, Koehrn K, LaLone CA, Laurenson JP, Leet JK, Lowit A, Lynn SG, Norberg-King T, Perkins EJ, Petersen EJ, Rattner BA, Sprankle CS, Steeger T, Warren JE, Winfield S, Odenkirchen E. Current ecotoxicity testing needs among selected U.S. federal agencies. Regul Toxicol Pharmacol 2022; 133:105195. [PMID: 35660046 PMCID: PMC9623878 DOI: 10.1016/j.yrtph.2022.105195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2021] [Revised: 05/19/2022] [Accepted: 05/25/2022] [Indexed: 10/18/2022]
Abstract
U.S. regulatory and research agencies use ecotoxicity test data to assess the hazards associated with substances that may be released into the environment, including but not limited to industrial chemicals, pharmaceuticals, pesticides, food additives, and color additives. These data are used to conduct hazard assessments and evaluate potential risks to aquatic life (e.g., invertebrates, fish), birds, wildlife species, or the environment. To identify opportunities for regulatory uses of non-animal replacements for ecotoxicity tests, the needs and uses for data from tests utilizing animals must first be clarified. Accordingly, the objective of this review was to identify the ecotoxicity test data relied upon by U.S. federal agencies. The standards, test guidelines, guidance documents, and/or endpoints that are used to address each of the agencies' regulatory and research needs regarding ecotoxicity testing are described in the context of their application to decision-making. Testing and information use, needs, and/or requirements relevant to the regulatory or programmatic mandates of the agencies taking part in the Interagency Coordinating Committee on the Validation of Alternative Methods Ecotoxicology Workgroup are captured. This information will be useful for coordinating efforts to develop and implement alternative test methods to reduce, refine, or replace animal use in chemical safety evaluations.
Collapse
Affiliation(s)
- Patricia Ceger
- Integrated Laboratory Systems, LLC, P.O. Box 13501, Research Triangle Park, NC, 27709, USA.
| | | | - David Allen
- Integrated Laboratory Systems, LLC, P.O. Box 13501, Research Triangle Park, NC, 27709, USA.
| | - Elyssa Arnold
- U.S. Environmental Protection Agency, Office of Pesticide Programs, MC7507P, 1200 Pennsylvania Avenue NW, Washington, DC, 20460, USA.
| | - Raanan Bloom
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
| | - Jennifer C Brennan
- U.S. Environmental Protection Agency, Office of Pollution Prevention and Toxics, 7401M, 1200 Pennsylvania Avenue NW, Washington, DC, 20460, USA.
| | - Carol Clarke
- U.S. Department of Agriculture, 1400 Independence Ave. SW, Washington, DC, 20250, USA.
| | - Karen Eisenreich
- U.S. Environmental Protection Agency, Office of Pollution Prevention and Toxics, 7401M, 1200 Pennsylvania Avenue NW, Washington, DC, 20460, USA.
| | - Kellie Fay
- U.S. Environmental Protection Agency, Office of Pollution Prevention and Toxics, 7401M, 1200 Pennsylvania Avenue NW, Washington, DC, 20460, USA.
| | - Jonathan Hamm
- Integrated Laboratory Systems, LLC, P.O. Box 13501, Research Triangle Park, NC, 27709, USA.
| | - Paula F P Henry
- U.S. Geological Survey, Eastern Ecological Science Center, 12100 Beech Forest Rd, Laurel, MD, 20708, USA.
| | - Katherine Horak
- U.S. Department of Agriculture, Wildlife Services National Wildlife Research Center, 4101 LaPorte Ave. Fort Collins, CO, 80521, USA.
| | - Wesley Hunter
- U.S. Food and Drug Administration, Center for Veterinary Medicine, HFV-161, 7500 Standish Place, Rockville, MD, 20855, USA.
| | - Donna Judkins
- U.S. Environmental Protection Agency, Office of Pesticide Programs, MC7507P, 1200 Pennsylvania Avenue NW, Washington, DC, 20460, USA.
| | - Patrice Klein
- U.S. Department of Agriculture, 1400 Independence Ave. SW, Washington, DC, 20250, USA.
| | - Nicole Kleinstreuer
- National Institute of Environmental Health Sciences, National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, P.O. Box 12233, Research Triangle Park, NC, 27709, USA.
| | - Kara Koehrn
- U.S. Environmental Protection Agency, Office of Pollution Prevention and Toxics, 7401M, 1200 Pennsylvania Avenue NW, Washington, DC, 20460, USA.
| | - Carlie A LaLone
- U.S. Environmental Protection Agency, Office of Research and Development, 8101R, 6201 Congdon Blvd., Duluth, MN, 55804, USA.
| | - James P Laurenson
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
| | - Jessica K Leet
- U.S. Geological Survey, Columbia Environmental Research Center (CERC), Columbia, MO, 65201, USA.
| | - Anna Lowit
- U.S. Environmental Protection Agency, Office of Pesticide Programs, MC7507P, 1200 Pennsylvania Avenue NW, Washington, DC, 20460, USA.
| | - Scott G Lynn
- U.S. Environmental Protection Agency, Office of Pesticide Programs, MC7507P, 1200 Pennsylvania Avenue NW, Washington, DC, 20460, USA.
| | - Teresa Norberg-King
- U.S. Environmental Protection Agency, Office of Research and Development, 8101R, 6201 Congdon Blvd., Duluth, MN, 55804, USA.
| | - Edward J Perkins
- U.S. Army Engineer Research and Development Center, 3909 Halls Ferry Rd., Vicksburg, MS, 39180, USA.
| | - Elijah J Petersen
- U.S. Department of Commerce, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD, 2089, USA.
| | - Barnett A Rattner
- U.S. Geological Survey, Eastern Ecological Science Center, 10300 Baltimore Ave, BARC-EAST Bldg. 308, Beltsville, MD, 20705, USA.
| | - Catherine S Sprankle
- Integrated Laboratory Systems, LLC, P.O. Box 13501, Research Triangle Park, NC, 27709, USA.
| | - Thomas Steeger
- U.S. Environmental Protection Agency, Office of Pesticide Programs, MC7507P, 1200 Pennsylvania Avenue NW, Washington, DC, 20460, USA.
| | - Jim E Warren
- U.S. Department of Agriculture, 1400 Independence Ave. SW, Washington, DC, 20250, USA.
| | - Sarah Winfield
- U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, HFS-009, College Park, MD, 20740, USA.
| | - Edward Odenkirchen
- U.S. Environmental Protection Agency, Office of Pesticide Programs, MC7507P, 1200 Pennsylvania Avenue NW, Washington, DC, 20460, USA.
| |
Collapse
|
7
|
Golusda L, Kühl AA, Siegmund B, Paclik D. Reducing Pain in Experimental Models of Intestinal Inflammation Affects the Immune Response. Inflamm Bowel Dis 2022; 28:801-807. [PMID: 34871378 PMCID: PMC9074866 DOI: 10.1093/ibd/izab290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Indexed: 12/09/2022]
Abstract
The incidence of inflammatory bowel disease with its two main manifestations, colitis ulcerosa and Crohn's disease, is rising globally year after year. There is still a tremendous need to study the underlying pathomechanisms and a well-established tool in order to better understand the disease are colitis models in rodents. Since the concept of the 3Rs was proposed by Russell and Burch, this would include pain medication in animal models of intestinal inflammation as a reduction of suffering. This review argues against pain medication because the administration of pain medication in its current form has an impact on the inflammatory process and the immune response, thus falsifying the results and the reproducibility and therefore leading to misconceptions.
Collapse
Affiliation(s)
- Laura Golusda
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, iPATH.Berlin, Berlin, Germany
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectious Diseases, and Rheumatology, Berlin, Germanyand
- Institute of Chemistry and Biochemistry, Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Berlin, Germany
| | - Anja A Kühl
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, iPATH.Berlin, Berlin, Germany
| | - Britta Siegmund
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectious Diseases, and Rheumatology, Berlin, Germanyand
| | - Daniela Paclik
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, iPATH.Berlin, Berlin, Germany
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectious Diseases, and Rheumatology, Berlin, Germanyand
| |
Collapse
|